Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.5 (market cap $16.72B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: iShares 3 7 Year Treasury Bond ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| IEI | XBI | |
|---|---|---|
Market Cap | $16.72B | $10.11B |
Volume | 3,963,319 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $120.72 | $169.55 |
52-Week Low | $113.17 | $104.99 |
Typical Hold Time | 43 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI trades at $113.465 with minimal daily movement (+0.07%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces resistance at $114 with support at $113. Recent dividend payments of $0.37-0.38 demonstrate consistent shareholder returns, though key financial ratios remain unavailable for fundamental assessment.
The bearish technical outlook and lack of fundamental data create uncertainty. Bond market volatility and rising Treasury yields present macroeconomic headwinds. Investment potential depends on forthcoming financial disclosures and the company's ability to navigate current interest rate environment.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
